| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
12,550 |
10,691 |
$392K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,918 |
6,768 |
$219K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
603 |
599 |
$42K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
425 |
423 |
$28K |
| 99050 |
|
1,792 |
1,686 |
$24K |
| 99490 |
Ccm add 20min |
1,656 |
1,656 |
$12K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
144 |
143 |
$12K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
155 |
154 |
$11K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,168 |
1,510 |
$9K |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
1,216 |
1,044 |
$9K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
206 |
190 |
$5K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
336 |
317 |
$4K |
| 92552 |
|
421 |
418 |
$3K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
62 |
56 |
$3K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
57 |
54 |
$3K |
| 81003 |
|
1,747 |
1,206 |
$3K |
| 0011A |
|
120 |
120 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
79 |
73 |
$973.00 |
| 0012A |
|
81 |
80 |
$730.63 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
95 |
91 |
$706.18 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
15 |
15 |
$633.22 |
| 87400 |
|
54 |
52 |
$607.51 |
| 0031A |
|
54 |
54 |
$340.68 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
30 |
30 |
$303.26 |
| 99497 |
|
96 |
90 |
$203.10 |
| 0013A |
|
17 |
17 |
$160.00 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
385 |
350 |
$130.66 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
12 |
12 |
$97.68 |
| 90662 |
|
74 |
74 |
$52.76 |
| 90715 |
|
25 |
25 |
$31.50 |
| J1020 |
Injection, methylprednisolone acetate, 20 mg |
25 |
25 |
$10.83 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
349 |
309 |
$4.20 |
| 91301 |
|
312 |
305 |
$0.08 |
| 91303 |
|
54 |
54 |
$0.02 |
| 90670 |
|
476 |
476 |
$0.00 |
| 99173 |
|
729 |
719 |
$0.00 |
| 90734 |
|
47 |
47 |
$0.00 |
| 90648 |
|
255 |
253 |
$0.00 |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
168 |
152 |
$0.00 |
| 90633 |
|
51 |
51 |
$0.00 |
| 3725F |
|
72 |
68 |
$0.00 |
| 90710 |
|
28 |
28 |
$0.00 |
| 90680 |
|
163 |
163 |
$0.00 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
40 |
37 |
$0.00 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
61 |
59 |
$0.00 |
| 90686 |
|
106 |
105 |
$0.00 |
| 90723 |
|
67 |
67 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
108 |
107 |
$0.00 |
| 1170F |
|
20 |
18 |
$0.00 |
| 90696 |
|
25 |
25 |
$0.00 |